Background: To determine whether time from surgery to initiation of chemotherapy impacts survival in advanced ovarian carcinoma.
To study this question further, we carried out an exploratory analysis on data collected on a phase III randomized trial in newly diagnosed ovarian carcinoma [4] .
methods background on GOG protocol 218
Gynecologic Oncology Group (GOG) protocol 0218 was a phase III, randomized, double-blind, placebo-controlled trial designed to determine whether the incorporation of bevacizumab with chemotherapy, and in the maintenance setting, improves progression-free survival (PFS) in women with newly diagnosed International Federation of Gynecology and Obstetrics stage III and IV ovarian, peritoneal, or fallopian tube carcinoma [4] . Patients with stage III disease and residual lesions ≤1 cm in maximal diameter were initially excluded but, after a protocol modification, they were permitted as long as gross macroscopic or palpable residual disease following surgery was present. Stage IV patients were eligible even if they had undergone complete resection in the abdomen. Patients were required to enroll between 1 and 12 weeks following surgery and begin cycle 1 within 14 days of randomization.
Between October 2005 and June 2009, 1873 patients were randomly assigned to one of three arms. At the time of primary analysis, a significant improvement in PFS was observed for the bevacizumab-throughout arm (i.e. carboplatin-paclitaxel-bevacizumab plus maintenance bevacizuamb) when compared with carboplatin-paclitaxel, with a hazard ratio (HR) of progression of 0.717 [05% confidence interval (CI) 0.625-0.824; P < 0.001] [4] . No significant differences in overall survival (OS) were observed. GOG 218 was the first of (thus far) eight phase III randomized trials involving five different antiangiogenesis drugs in primary or recurrent ovarian carcinoma to meet its primary end point, and led directly to European Medicines Agency approval of bevacizumab in newly diagnosed ovarian cancer [4, 5] .
ancillary data statistical analysis
Clinical and pathologic data were collected and underwent univariate and multivariate analyses. Categorical variables were compared between subgroups by the Pearson's χ 2 test and continuous variables by the Wilcoxon-MannWhitney test or the Kruskal-Wallis test [6] [7] [8] . Survival was estimated using the Kaplan-Meier method [9] . The Cox proportional hazards model was used to evaluate independent prognostic factors and to estimate their covariateadjusted effects on survival [10] . Adjusted survival curves were derived from the Cox OS model. Survival probabilities were calculated at every failure time of the whole population, using representative covariate values for adjustment [11] . Continuous variables (e.g. time to initiation of chemotherapy) exhibiting skewed distribution were included in the survival model after log transformation, and the nonlinearity of the effect was assessed using restricted cubic splines, which in turn were validated by Molinari's threshold selection method [12, 13] . All statistical tests were two-tailed with the significance level set at α = 0.05. Statistical analyses were carried out using the R programming language and environment [14] .
results
Of 1837 patients enrolled, 1718 were evaluable in this analysis. Clinical and pathologic characteristics of patients were reported in the original publication and are contained in supplementary  Table S1 , available at Annals of Oncology online. The median time from surgery to initiation of chemotherapy in each arm was 31 days (interquartile range, 23-41 days).
For 467 patients (27%), time from surgery to initiation of chemotherapy was >40 days (5.5 weeks). Initiation of therapy under 25 days was not associated with an increased risk of death due to wide CIs, but after 25.0 days (95% CI 16.6-49.9 days), the risk appears to increase sharply ( Figure 1A ). The time interval from surgery to initiation of chemotherapy was not associated with further treatment delays beyond cycle 1, grade 3-4 toxicity, dose reductions, or PFS (adjusted hazard of progression 1.06; 95% CI 0.94-1.18; P = 0.347).
In the study population, 54.2% had large-volume residual disease (i.e. residual disease >1 cm), 40.8% had low-volume residual disease (≤1 cm), and 4.9% underwent complete resection Relationship between the interval between surgery and initiation of chemotherapy and log hazard ratio for each disease residual group. The lighter lines around each partial effects curve represent point-wise 95% confidence intervals. The figure suggests that the complete resection group is most affected by a longer interval from surgery to chemotherapy, whereas the other groups are affected very little. Importantly, this observation applies only to stage IV patients (81 of 477 had undergone complete resection); patients with stage III disease were required to have macroscopic visible/palpable residual disease following surgery. Note that the associated risk of time from surgery to initiation of chemotherapy is flat (15 days) or increasing (40 days, specifically for microscopic patients). The AHR denotes the change in risk of death associated with an increase of 1 year in age.
b
The AHR for a covariate involved in an interaction is given for representative values of the other covariates in the interaction. The AHR denotes the change in risk of death associated with a 10% increase in CA 125 (µg/ml). and were rendered R 0 (i.e. microscopic residual) ( Table 1 ). The OS model (Table 2 ) and effects plot ( Figure 1B) suggests that the microscopic residual group is most affected by a long interval P < 0.001), whereas the other groups are affected very little. For White patients with complete resection, for example, the risk of death increases by 27% in the increasing part of their respective curve, i.e. after ∼25 days, for every 10% lengthening of time from surgery to initiation of chemotherapy (TSIC). Note that, at 15 days, time to initiation of chemotherapy does not increase the risk of death for any patients, whereas at 40 days most patients have an increased risk of death. This represents a change-point in increasing time at which some patients start to become affected negatively. The OS model given in Table 2 also included a moderate time from surgery to initiation of chemotherapy × race/ethnicity interaction (P = 0.019). The HRs show that Asian patients were susceptible to risk from longer time from surgery to initiation of chemotherapy regardless of residual status. Figure 2 shows a set of adjusted survival curves for a 'typical' patient in GOG 218 with large-volume tumor residual (>1 cm, 1A), optimally debulked (≤1 cm, 2B), and no gross residual (2C), with various lengths of time from surgery to initiation of chemotherapy in days. The three curves in Figure 2Aand B represent the survival of three typical patients whose covariate values were exactly the same (including large-volume residual disease or optimally debulked) except for time from surgery to initiation of chemotherapy, which is fixed at 20, 40, and 60 days for each curve. Note that the curves keep fairly close together over time. In Figure 2C , however, the situation is different. For three typical patients with complete resection and otherwise identical covariate values, varying time from surgery to initiation of chemotherapy spreads the curves farther apart so that the survival probability drops off more quickly with increasing time from surgery to initiation of chemotherapy.
discussion
For the 81 patients with stage IV disease who underwent complete resection, this exploratory analysis indicates that the risk of death increased when the time from surgery to initiation of chemotherapy exceeded 25 days. Patients were permitted to enroll up to 12 weeks from surgery and therefore initiation of chemotherapy after 25 days was not considered a 'delay in therapy' as long as it was started before 84 days had elapsed (i.e. 12 weeks). Reasons for initiating chemotherapy after 25 days were therefore not collected but may have been related to the time required to obtain insurance authorizations for referral to oncology, lack of health care insurance, or increased recovery time required by patients in the complete resection group who underwent extensive cytoreductive procedures and possibly experienced more postoperative complications. The more medically infirm and/or those who were increasingly symptomatic due to a large tumor burden may have been too sick to initiate chemotherapy immediately. Given that our findings concerning microscopic residual disease pertain only to those with stage IV disease (since stage III rendered R 0 were not eligible), it is possible that, without expeditious initiation of chemotherapy, recurrent pleural effusions/upper abdominal tumor regrowth may have had a significant detrimental impact on outcome. The correlation between time to chemotherapy and residual disease is unlikely to be a false positive because the model is fairly small with only the time to initiation of chemotherapy and nine covariates known to be prognostic for survival in this disease and the interaction is quite strong (P < 0001).
One year after Magrath's 1974 report on improved survival in patients with abdominal Burkitt's lymphoma who underwent cytoreduction of the intra-abdominal tumor burden, Griffiths demonstrated an inverse relationship between residual tumor diameter following abdominal surgery and survival among 100 consecutive patients with ovarian cancer [15, 16] . In the 2002 meta-analysis by Bristow et al. involving 6886 patients with stage III and IV ovarian carcinoma treated with platinum-based chemotherapy, maximal cytoreduction was found to be the most important determinant of survival [17] . Complete resection leaving only microscopic residual disease (i.e. no gross residual designated R 0 ) sets the stage for platinum-and taxane-based chemotherapy [18] . However, as stated earlier, perioperative complications associated with extended cytoreductive surgery may lead to a protracted postoperative convalescence, ultimately resulting in a delay in initiation of chemotherapy [19] . The impact of time from surgery to initiation of chemotherapy on outcome in patients with solid tumors has been previously investigated (Table 3 ) [3, [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] . The most extensive research includes four Medicare-linked Surveillance Epidemiology and End Results (SEER) database studies in ovarian, breast, colon, and rectal cancer, and a metaanalysis of three phase III trials in ovarian cancer [19] [20] [21] [22] .
The interval between resection and chemotherapy may provide opportunity for micrometastases to proliferate as the curable fraction with microscopic residual may be most sensitive to this effect. The biological mechanism to account for this vulnerability is suggested by multiple experimental observations. In animal models developed to assess classical and hyperexponential Gompertzian growth kinetics, surgical resection leads to accelerated metastatic tumor growth due to shuttling of noncycling cells in G 0 phase into the cell cycle [30, 31] . Using a murine mammary adenocarcinoma, Fisher et al. detected that the shorter the interval between operation and cyclophosphamide administration, the more complete the abrogation of the kinetic changes in distant tumor foci, the more effective suppression of residual tumor, and the more prolonged the survival [32] . Residual disease following cytoreductive surgery may have a high growth fraction making it more susceptible to cell cyclespecific drugs (e.g. taxanes). These principles following complete resection may also apply to stage I-III. In this study, a lack of impact of initiation of chemotherapy on PFS may have resulted from the relative indeterminacy of PFS when compared with death as an end point and also because both RECIST and increasing CA 125 were permitted in GOG 218 to document progression.
Cytoreduction results in increased proliferation of microscopic residual disease and depletion of endogenous antiangiogenesis factors [33] . Early initiation of chemotherapy plus exogenous antiangiogenesis therapy may not be as critical to those with gross residual disease for whom these subtle biological phenomena may not be relevant. Given the hierarchy of angiogenesis pathways and the genomic instability which governs ovarian carcinoma, the potential to favorably exploit time from surgery to initiation of chemotherapy through manipulation of the microenvironment with angiogenesis inhibitors is implicit (supplementary Figure S1 , available at Annals of Oncology online). Finally, the vulnerability to Asian patients with lengthening interval from surgery to initiation of chemotherapy found in this study may be related to ethnic differences in the expression of allelic variants that produce altered pharmacokinetics of anticancer drugs, including paclitaxel in Asians, or to certain genetic polymorphisms recognized for their role in intrinsic and/or acquired drug resistance [34, 35] .
The time interval within which postoperative chemotherapy for ovarian cancer should be initiated is unknown. Neither National Comprehensive Cancer Network guidelines nor those published by the American Society of Clinical Oncology specify explicitly a time interval within which chemotherapy for ovarian cancer should be initiated. Patients managed at tertiary centers may be treated earlier following surgery and these patients may have access to more treatment options for management of recurrent disease, making the time interval from surgery to the initiation of first-line chemotherapy a confounding factor for survival. A further limitation previously noted was that because enrollment was permitted up to 12 weeks following surgery, the reasons for initiating treatment after certain intervals (e.g. 25 days) were not collected.
Forthcoming trials should be designed to examine the relationship between time to initiation of chemotherapy and survival end points as a protocol-specified exploratory objective and track reasons that may contribute to treatment initiation 'delays'. Prospective evaluation of identifiable clinical factors that lengthen the time from surgery to initiation of chemotherapy (e.g. perioperative complications, patient behavioral factors, health care system logistic factors) could be formally assessed. This will allow for better delineation of disease-specific mortality as a function of treatment delay and/or perioperative events and medical co-morbidities. Some oncologists have advocated for centralization of ovarian cancer cytoreduction to high-volume cancer centers with access to clinical trials, similar to what has [36] . Centralization may also carry with it the added benefit of increasing patient access to the 25-day window which may be important as suggested by these data.
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